Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for PhaseBio Pharmaceuticals (PHAS : NSDQ)
 
 • Company Description   
PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States.

Number of Employees: 60

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.93 Daily Weekly Monthly
20 Day Moving Average: 539,956 shares
Shares Outstanding: 48.69 (millions)
Market Capitalization: $45.28 (millions)
Beta: 1.98
52 Week High: $4.24
52 Week Low: $0.89
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.40% -17.16%
12 Week -29.01% -22.98%
Year To Date -64.37% -57.63%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1 Great Valley Parkway Suite 30
-
Malvern,PA 19355
USA
ph: 610-981-6500
fax: -
john.sharp@phasebio.com http://www.phasebio.com
 
 • General Corporate Information   
Officers
Jonathan P. Mow - Chief Executive Officer
Clay B. Thorp - Chairman
John P. Sharp - Chief Financial Officer
Edmund P. Harrigan - Director
Nancy J. Hutson - Director

Peer Information
PhaseBio Pharmaceuticals (CORR.)
PhaseBio Pharmaceuticals (RSPI)
PhaseBio Pharmaceuticals (CGXP)
PhaseBio Pharmaceuticals (BGEN)
PhaseBio Pharmaceuticals (GTBP)
PhaseBio Pharmaceuticals (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 717224109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 48.69
Most Recent Split Date: (:1)
Beta: 1.98
Market Capitalization: $45.28 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.59 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.22 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 4.14
EPS Growth
vs. Year Ago Period: 73.56%
vs. Previous Quarter: 74.44%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -25.95%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -144.23
12/31/21 - -154.33
09/30/21 - -143.64
Current Ratio
03/31/22 - -
12/31/21 - 1.75
09/30/21 - 3.04
Quick Ratio
03/31/22 - -
12/31/21 - 1.75
09/30/21 - 3.04
Operating Margin
03/31/22 - -1,049.18
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -1,049.18
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -1,195.37
09/30/21 - -1,093.85
Book Value
03/31/22 - -
12/31/21 - -1.93
09/30/21 - -1.05
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©